In patients with AAT-1 deficiency, intravenous administration of AAT-1 in a dose of 60 mg per kg body weight maintain plasma levels resembling acute phase response immediately after administration, and retain an appropriate level of serum AAT above the protective threshold (50 mg/dl) a week afterwards (39).